Oxford BioMedica stock opened at GBX 10.96 ($0.15) on Wednesday. Oxford BioMedica has a 1-year low of GBX 4.44 ($0.06) and a 1-year high of GBX 13.19 ($0.19).
In other Oxford BioMedica news, insider Peter Nolan purchased 371,450 shares of the business’s stock in a transaction on Thursday, April 5th. The shares were bought at an average cost of GBX 11 ($0.15) per share, for a total transaction of £40,859.50 ($57,354.72). Also, insider Lorenzo Tallarigo purchased 22,066 shares of the business’s stock in a transaction on Thursday, March 22nd. The stock was acquired at an average price of GBX 12 ($0.17) per share, for a total transaction of £2,647.92 ($3,716.90). Over the last 90 days, insiders acquired 415,637 shares of company stock worth $4,616,194.
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.